Advanced 3D liver models for toxicity testing and disease modeling
Defining a new in vitro standard for toxicity testing
Developing new drugs is expensive and time-consuming. The process of shepherding one new drug through discovery, preclinical testing, and clinical trials is estimated to cost between $500 million and $1.2 billion USD. Chances that a drug will fail at any stage of development are enormous. Safety-related issues remain the primary reason for drug failure, largely because predicting which drugs will prove toxic in patients is extremely difficult. Traditional approaches to toxicity and safety testing, while well established, are inherently flawed. Widely used sandwich culture and 2D in vitro models are hindered by limited throughput, loss of cell viability, and decreases in measurable tissue-specific functionality. In vivo animal tests are expensive, raise moral and ethical issues, and often fail to reveal important signs of toxicity in humans.
Why do the world's largest pharmas choose InSphero liver microtissues?
InSphero offers a better in vitro model for early detection of hepatotoxicity. We understand the toxicity testing workflow, and have years of experience working with 3D in vitro technology, which have helped us develop a comprehensive suite of products and services designed to simplify compound screening. What’s so special about InSphero? Our liver microtisssues are engineered to recapitulate the smallest functional unit of a tissue or organ, providing a morphological and functional analog to native liver tissue. InSphero bridges the gap between in vitro and in vivo toxicity testing models to provide solutions that are:
- More sensitive to drug-induced liver injury (DILI)
- More mechanistically accurate (e.g., maintain phase I drug metabolism)
- More predictive of human biological responses
Debating whether to make or buy your liver microtissues? Read this first.
InSphero 3D InSight™ Liver Microtissues are next-generation 3D models for DILI and investigative toxicity testing. Using the 3D Select™ Process, we ensure only the most viable hepatocytes incorporate into our microtissues, improving viability and organotypic morphology. When compared head-to-head to conventional production methods, there is no comparison. See the results in our White Paper:
Perfecting cellular self-assembly: Prerequisites for industrial-scale production of 3D microtissues for drug discovery and development.